TY - JOUR
T1 - The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia
AU - Gonzalez-Lugo, Jesus D.
AU - Chakraborty, Samarpana
AU - Verma, Amit
AU - Shastri, Aditi
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments.
AB - Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments.
UR - http://www.scopus.com/inward/record.url?scp=85099551798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099551798&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2020.12.003
DO - 10.1053/j.seminhematol.2020.12.003
M3 - Article
C2 - 33509444
AN - SCOPUS:85099551798
SN - 0037-1963
VL - 58
SP - 56
EP - 65
JO - Seminars in hematology
JF - Seminars in hematology
IS - 1
ER -